Definium Therapeutics
@definiumtx.com
Definium Therapeutics (Formerly MindMed) is forging a new era in psychiatry by harnessing the full therapeutic potential of psychedelic medicine.
Definium Therapeutics's Company Logos
Definium Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#007CBA
Lochmara
0, 124, 186
200, 100, 36
100, 33, 0, 27
#161512
Rangoon Green
22, 21, 18
45, 10, 8
0, 5, 18, 91
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
About Definium Therapeutics
Definium Therapeutics is a dynamic biotechnology company incorporated in British Columbia in 2010, with its headquarters located at One World Trade Center, New York. The company specializes in developing innovative therapies aimed at treating various diseases, focusing on advancing scientific research and product development in the therapeutic space. Definium went public in February 2020 through a reverse takeover, subsequently uplisting to NASDAQ under the symbol DFTX in April 2021.
With a commitment to transparency and investor relations, Definium provides access to its financial results and SEC filings for stakeholders. Although the company does not currently pay dividends or offer a direct stock purchase plan, it focuses on strategic growth and scientific advancement. Definium Therapeutics is dedicated to improving patient outcomes through groundbreaking research and is poised for future developments in the biotechnology field, aligning its efforts with the needs of both investors and the healthcare community
Related Brands
Tags
Psychedelic medicine
Psychiatric drug development
LSD-based therapeutics
Phase 3 clinical trials
Neuroscience and clinical research
